January 24, 2022 8:01am

A very weak pre-market indication

Pre-open indications: 5 SELL and 2 BUYs (Hope and a Prayer) and 1 PUMP/PROMOTE

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

Only the facts …

 


Dow futures are DOWN -0.31% (-105 points), S&P futures are DOWN -0.45% (-21 points) and NASDAQ futures are DOWN -0.74% (-112 points)

 

Stock futures rose early Monday, following the S&P 500′s worst week since March 2020,

European stocks were lower as investors braced themselves for the U.S. Fed meeting, and watched Ukraine as tensions with Russia grow,

Asia-Pacific markets traded mixed with same reasons as above,

 

Henry’omics

The sell-off in the Nasdaq was even more severe with the benchmark dropping 7.6% last week, notching its fourth (4th) straight weekly loss. The index now sits more than 14% below its November record close, falling deeper into correction territory. <CNBC>

The week issue revolves around how the Fed’s policy meeting, which signals on how much the central bank will raise interest rates this year and when it will start on Wednesday.

 

Economic data Docket: The Federal Open Market Committee is due to meet on Tuesday and Wednesday to decide on the next steps for U.S. monetary policy.

 

If you didn’t remember what happen in Friday’s close, you won’t be prepared for today’s session:

RegMed Investors’ (RMi) closing bell: “sector trades accelerate risk aversion tumbles. Another low for this week with an option expiration Friday.” …  https://www.regmedinvestors.com/articles/12267

Ebb and flow – January and Q1 to date:

  • 1 holiday, 1 neutral, 10 negative and 3 positive closes

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Probabilities/ Potentials pre-open share pricing indication moves:

SELL: headed down …

Alnylam Pharmaceuticals (ALNY) closed down (Friday) -$1.90 to $136.41 a with a negative -$1.41 or -1.03% pre-open indication.

Cellectis SA (CLLS) closed down (Friday) -$0.11 to $6.62 with a negative -$0.30 or -4.53% pre-open indication

CRISPR Therapeutics (CRSP) closed down -$1.75 to $62.61 with a negative -$2.20 or -3.51% pre-open indication

Global Blood Therapeutics (GBT) closed down -$0.25 to $26.54 with a negative -$0.52 or -1.96% pre-open indication.

Intellia Therapeutics (NTLA) closed down -$1.10 to $81.52 with a negative -$1.02 or -1.25% pre-open indication,

 

BUY: a hope and a prayer …

AxoGen (AXGN) closed down -$0.28 to $8.28 with a positive +$0.05 or +0.60% pre-open indication.

Voyager Therapeutics (VYGR) closed down -$0.07 to $2.83 with a positive +$0.04 or +1.41% pre-open indication

 

Maintaining SELL:

Biostage (OTCQB: BSTG) closed up again +$0.20 with 3,941 shares traded after Wednesday’s +$0.25 to $4.00 with 1,516 shares traded, Tuesday’s -$0.85 to $3.75 and last Friday’s flat at $4.60.

  • First question, WHERE is the volume coming from?
  • Is there a reason for the “pump and promote”; are they trying to reverse or convert the non-registered shares from the multiple overpriced private placement (without any valuation models) to register shares to “facilitate” an “equity raise” to protect/satisfy tired non-U.S. investors?

 

 

The BOTTOM LINE: The sector’s dive continued to hit new lows with a possible fourth (4rd) new low in a row.

It won't be surprising to see the sector bounce lower, although some/few moves to the upside.

52-week lows experiences last week:

  • IBB hit a 52-week low of 129.05
  • XBI hit a 52-week low of 90.74
  • Cellectis SA (CLLS) hit a 52-week low of $6.60
  • Verastem (VSTM) hit a 52-week low of $1.48
  • Regenxbio (RGNX) hit a 52-week low of $25.02
  • Applied Genetic Technologies (AGTC) hit a 52-week low of $1.61
  • CRISPR Therapeutics (CRSP) hit a 52-week low of $63.15
  • Precigen (PGEN) hit a 52-week low of $2.93
  • Sangamo Therapeutics (SGMO) hit a 52-week low of $5.85
  • Solid BioSciences (SLDB) hit a 52-week low of $1.31
  • Adverum Biotechnologies (ADVM) hit a 52-week low of $1.52
  • Fate Therapeutics (FATE) hit a 52-week low of $37.50
  • Editas Medicine (EDIT) hit a 52-week low of $18.45
  • bluebird bio (BLUE) hit a 52-week low of $18.33

Reiterating, “Patience is key. Don't jump the gun, but don't walk away. As I have stated, the oversold usually “pop” after steady declines so, stay “pat”, buying a few decliners or staying in cash.”

One factor to the decline is earnings season right around the corner.

I am NOT changing my position, “Brace for more choppiness as we move further into the month and the beginning of Q4/21 Q4 and end-of-year numbers”.

  • I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors

So, my bottom of the Bottom Line, Investors should be extremely cautious about adding any new exposure.

  • RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

WHY do I keep reporting on Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in FATE, CRS, securities referred to in this publication.